Miragen Therapeutics

MGEN NASDAQ
2.330
+0.070
+3.10%
Closed 16:00 07/18 EDT
Open
2.270
Prev Close
2.260
High
2.460
Low
2.270
Volume
75.33K
Avg Vol (3M)
188.53K
52 Week High
7.25
52 Week Low
2.010
% Turnover
0.24%
Market Cap
72.07M
1D
5D
1M
3M
1Y
5Y

Company Profile

Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155 (miR-155), which is found at abnormally high levels in several blood cancers. The Company's clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is involved in discovering and developing a pipeline of pre-clinical product candidates. Its pre-clinical product candidates include MRG-107 and MRG-110.
MORE >

Recently

Name
Price
%Change